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A humanized monoclonal antibody against ERBB2 is used in neoadjuvant 
therapy for gastric cancer patients. A critical factor in determining patient 
eligibility and predicting outcomes of this therapy is the intratumoral 
heterogeneity of ERBB2 amplification in gastric adenocarcinomas. The aims of 
this study are to assess the underlying mechanisms of intratumoral 
heterogeneity of ERBB2 amplification and to characterize the diversity of 
co-amplified oncogenes, such as EGFR, FGFR2, MET, MYC, CCND1 and 
MDM2 and to examine the usefulness of multiple ligation-dependent probe 
amplification (MLPA) in the semi-comprehensive detection of these gene 
amplifications. A combined analysis of immunohistochemistry and 
fluorescence in situ hybridization (FISH) revealed ERBB2-amplified cancer 
cells in 51 of 475 formalin-fixed paraffin-embedded gastric adenocarcinomas. 
The fraction of amplification-positive cells in each tumor ranged from less than 
10% to almost 100%. Intratumoral heterogeneity of ERBB2 amplification, 
defined as less than 50% of cancer cells positive for ERBB2 amplification, was 
found in 41% (21 of 51) of ERBB2-amplifiedtumors. The combined analysis of 
MLPA and FISH revealed that ERBB2 was co-amplified with EGFR in seven 
tumors, FGFR2 in one tumor, and FGFR2 and MET in one tumor; however, 
the respective genes were amplified in mutually exclusive cells. Coexistence of 
coamplified ERBB2 and MYC within single nuclei in four tumors and one of 
these cases had suspected co-amplification in the same amplicon of ERBB2 
with MYC. In conclusion, the amplification status of ERBB2 and other genes 
can be obtained semi-comprehensively by MLPA and could be useful to plan 













Gastric cancer is the fourth most common human malignancy and the second 
most common cause of cancer-related death worldwide (1). The clinical 
outcome of gastric cancer has gradually improved, however the prognosis of 
patients with advanced disease is still dismal. Gastric carcinomas in the initial 
stages, such as early gastric carcinomas as defined by the Japanese Gastric 
Cancer Research Society (2), are carcinomas that are confined to the mucosa 
and the submucosa that are usually endoscopically or surgically resectable and 
can be cured (3). However, the majority of patients with advanced gastric 
carcinomas, defined as carcinomas that penetrate the muscle layer or beyond 
(2), have metastatic lesions and/or inoperable carcinomas and have a poor 
prognosis (4). Thus, novel therapeutic modalities are urgently needed for the 
treatment of late-stage gastric carcinomas. One potentially useful approach is 
the molecular targeting of ERBB2 (5, 6). 
ERBB2 (also called HER2) is a 185-kDa transmembrane tyrosine kinase 
receptor. Overexpression as a result of ERBB2 gene amplification on 
chromosome 17q11.2-q12 has been observed in solid tumors including gastric 
and breast cancers (7). ERBB2 is amplified in 7%-27% of gastric cancers 
(8-11). In breast cancers, overexpressed ERBB2 is a therapeutic target of 
trastuzumab, a humanized monoclonal antibody that binds to the extracellular 
juxtamembrane domain of ERBB2 and inhibits the proliferation and survival of 
ERBB2-overexpressing cancer cells (12). In 2009, an open-label, international 
phase 3, randomized controlled trial (ToGA, Trastuzumab for gastric cancer) 
found that the addition of trastuzumab to cisplatin-based chemotherapy 
significantly improved the overall survival of advanced gastric cancer patients 
with over-expressed and/or amplified ERBB2 as compared to chemotherapy 
alone (13). As the target of therapy with trastuzumab, the evident difference 
between gastric cancer and breast cancer is the intratumoral heterogeneity of 
ERBB2 amplification (7).  
It is noteworthy that recent comprehensive genomic analyses of copy 
number alterations with a high-resolution single nucleotide polymorphism 
array (14) and oligonucleotide array comparative genomic hybridization 
(aCGH) (15) revealed that genes encoding receptor tyrosine kinases (RTKs), 
such as ERBB2, FGFR2, MET and EGFR, in addition to MYC, CCND1 and 
MDM2 were frequently amplified in gastric cancers. It is most likely that 
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intratumoral heterogeneity of ERBB2 amplification is based on the common 
chromosomal instability where new amplification of some of these genes 
begets new cancer cells that are dispensable with ERBB2 amplification, or 
co-amplification of new genes with ERBB2 gives sister cancer cells additional 
or synergistic growth advantages(16). 
  In tumors with genetic heterogeneity, the genomic landscape, as determined 
by results from single gene aberration assays, is critical for 
personalized-medicine strategies. For example, when molecularly targeted 
therapy against ERBB2 is used, ERBB2-negative cancer cells, if any, may 
survive or exhibit overgrowth after ERBB2-positive cancer cells have been 
killed, as we have previously reported in a case of breast cancer (17). Thus, the 
semi-comprehensive analysis of therapy-related genes is mandatory. Multiplex 
ligation-dependent probe amplification (MLPA) is a new, high-resolution 
method for detecting numerous copy number variations in genomic sequences 
in a single reaction requiring only small amounts of DNA extracted from 
formalin-fixed paraffin-embedded (FFPE) tissues (18, 19).  Now a detection 
kit for ERBB2, EGFR, MET, MYC, CCD1 and MDM2 and one for FGFR2, 
which we utilized in the present study, have been commercially available.  
In the present study, we sought to identify the heterogeneity of ERBB2 
amplification in gastric cancers and to characterize the possible diversity of 
amplified oncogenes with or without ERBB2 amplification. To achieve these 
goals, we tested the reliability of the recently developed MLPA as a tool to 
semi-comprehensively detect molecular changes.  
 
 
Materials and Methods 
 
Patients 
A total of 475 patients with gastric adenocarcinoma (310 early and 165 
advanced tumors) who underwent surgery or endoscopic resection at the 
Department of Surgery in Kanazawa University Hospital between 2005 and 
2010 were examined. Cancer staging was performed according to the TNM 
cancer staging system of the American Joint Committee of Cancer (20). The 
World Health Organization Classification of Tumors (21) was used to 
determine histological classification, i.e., as differentiated (tubular 
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adenocarcinoma, papillary adenocarcinoma) or undifferentiated 
adenocarcinoma (mucinous adenocarcinoma, poorly cohesive carcinomas, 
mixed carcinoma, carcinoma with lymphoid stroma and unclassified 
carcinoma). This laboratory study was approved by the Institutional Review 
Board at Kanazawa University Hospital (Approval No 181), and written 
informed consent was obtained from all patients. Serial sections cut from 
representative FFPE cancer tissues were used for hematoxylin-eosin staining, 
immunohistochemistry (IHC), MLPA and FISH.  
 
IHC 
IHC for ERBB2 and EGFR proteins was performed on all primary tumors. A 
polyclonal antibody against the internal domain of the human ERBB2 protein 
(Nichirei, Tokyo, Japan; working dilution, 1:400) and a monoclonal antibody 
against the external domain of human EGFR (Novocastra Lab, Newcastle, UK; 
working dilution, 1:20) were used. Antibody binding was visualized by the 
LSABTM system (Dako, Glostrup, Denmark). For evaluation of the positivities, 
each tumor, or portion of tumor, was scored using a four-tier system (0, 1+ - 
3+) according to the criteria recommended by Dako for the HercepTestTM, 
except that the quantity of positive cells was not considered.        
 
FISH 
Areas with positive IHC staining (2+ and 3+) for ERBB2 and EGFR, , and 
areas with amplification and gain of FGFR2, MET, MYC, CCND1, CDK4, 
MDM2, as determined by MLPA, were examined for gene amplification by 
FISH. When the gene amplification was positive in the primary tumors, their 
nodal metastases then underwent FISH examination for amplification of the 
genes. 
  For FISH probes, bacterial artificial chromosomes RP11-62N23, 
RP11-339F13, RP11-62L18, RP11-75I20, RP11-440N18, RP11-775J10, 
RP11-300I6, and RP11-571M6, specific to ERBB2, EGFR, FGFR-2, MET, 
MYC, CCND1, CDK4 and MDM2, respectively, were acquired from BACPAC 
Resources (Oakland, CA) and labeled with SpectrumOrangeTM or 
SpectrumGeenTM with a nick translation kit (Abbott Laboratories, Abbott Park, 
IL). For the detection of gene amplification, a SpectrumGreenTM-labeled 
pericentromeric probe (Abbott), specific to each chromosome on which the 
particular gene was located, was co-hybridized to standardize the chromosome 
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number. The tumors exhibiting co-amplifications of different genes were 
further examined by simultaneous hybridization with two probes specific to the 
genes labeled by different fluorescent markers to determine the co-existence of 
the amplified genes in single cells and single amplicons. 
The removal of protein from the tissue sections was conducted as 
previously described (10). Denaturation, hybridization, and post-hybridization 
washing were performed according to Abbott’s protocol. The tissue sections 
were counterstained with DAPI II (Abbott) and examined with a fluorescence 
microscope (Olympus, Tokyo, Japan) equipped with a Triple Bandpass Filter 
set (Abbott) for DAPI II, SpectrumOrangeTM and SpectrumGreenTM, and a 
filter set specific to SpectrumOrangeTM or SpectrumGreenTM. The FISH images 
were recorded through a cooled charge-coupled device camera (DP-70) linked 
to a computer software program (DP Manager, Olympus). 
FISH results were scored manually, and gene amplification was 
determined according to the American Society of Clinical Oncology/College of 
American Pathologists–approved criteria of ERBB2 amplification, which is 
more than six gene copies per nucleus or gene signals/centromere signals > 2.2 
(22). The fraction (%) of the ERBB2-amplified tumor cells, and sizes of the 
tumor areas occupied by the ERBB2-amplified tumor cells were determined in 
the representative sections using IHC and FISH. The tumors with less than 
50% of ERBB2-amplified cells were arbitrarily defined as tumors with the 
heterogeneous amplification of the ERBB2. 
. 
MLPA 
To efficiently identify co-amplified genes and genes that were amplified 
exclusively with ERBB2, MLPA was performed separately, if possible, in the 
ERBB2-amplified tumor areas and the non-amplified areas. Combined with 
IHC and FISH, the ERBB2-amplified tumor areas and the non-amplified areas, 
if any, were identified in the FFPE tissues on glass slides. By using adjacent 
6µm-thick sections, DNA was extracted manually from each section according 
to the manufacturer’s protocol. Amplified areas that were as large as possible 
were selected to obtain ample DNA, but at the same time the 
ERBB2-non-amplified cancer cells and non-neoplastic cells were excluded as 
much as possible. The ERBB2-non-amplified areas were selected to exclude 
amplified cells as much as possible. As a result, more than 1µg DNA samples 
each with OD260:OD280 ratios within 1.1 -1.7 were obtained from 
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ERBB2-amplified areas in all 51 tumors, and in 20 of these tumors samples 
were obtained from both the amplification-positive and amplification-negative 
areas.  
 Forty gastric cancers without ERBB2 amplification were selected at random 
from 314 differentiated-type gastric adenocarcinomas for DNA examination. 
DNA from cell lines MKN7, A431, KATOIII, HSC39, and MKN45, which had 
previously been confirmed to have amplified ERBB2, EGFR, FGFR2, FGFR2 
and MYC, and MET, respectively, were used as positive controls (23, 24).  
MLPA analysis was performed by using two kits from MRC-Holland 
(Amsterdam, The Netherlands). The SALSA MLPA KIT P175-A2 
Tumour-Gain kit contains probes for 24 genes including ERBB2, EGFR, MET, 
MYC, CCND1 and MDM2, and the SALSA MLPA probemix P231-A2 
FGF10-FGFR2 contains probes for FGFR2 and FGF10. The MLPA PCR 
products were separated on an ABI-310 capillary sequencer (Applied 
Biosystems, Foster City, CA) and interpreted with Genemapper software 
(Applied Biosystems). Data analysis was performed with Coffalyser 
MLPA-DAT software (version 9.4, MRC-Holland) to generate normalized 
peak values. Peak values below 0.7 were defined as lost, between 0.7 and 1.3 
as normal, between 1.3 and 2.0 as gain, and >2.0 as amplified, as previously 





Amplification of ERBB2 
 Among a total of 475 tumors ERBB2 overexpression by IHC was found in 
60 tumors. By FISH, 51 of 60 ERBB2-overexpressing tumors (8 tumors with 
2+ overexpression and 43 tumors with 3+ overexpression) had gene 
amplification of ERBB2, most of them appeared as tightly clustered or 
numerous scattered signals, suggesting amplicons in homogeneously staining 
regions (HSR) or double minute chromosomes (DM). (25) ERBB2 
amplification was significantly more frequent in differentiated carcinomas than 
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in undifferentiated carcinomas (p=0.0078). Among the 51 tumors, 23 were 
advanced gastric cancers. No significant correlation was found between the 
existence or extent of ERBB2 amplification and the location, T stage or N stage 
of the tumor. The amount of amplification-positive cells in each tumor ranged 
from almost all cancer cells (Fig. 1A), to small distinct clusters (Fig. 1B, 
arrow), or confluent tubules (Fig. 1C&D), which accounted for less than 10% 
of the total cancer cells. Otherwise, the amplified and non-amplified tumor 
cells were mosaic admixed (Fig. 1E&F). Fractions of the ERBB2-amplified 
cells and sizes of areas occupied by the amplified cells in each tumors were 
shown in Table1. Tumors with intratumoral heterogeneity of ERBB2 
amplification was found in 21 (41%) of the 51 tumors. The numbers of tumors 
with different fractions of the ERBB2-amplified cells were summarized 
separately in advanced and early gastric cancers in Figure 2. 
 
MLPA analysis of amplification of ERBB2 
The MLPA analyses was successfully performed on all of the FFPE samples. 
The mean MLPA peak values of the 51 tumors with FISH-proven 
ERBB2-amplification are shown in Table 1. Among the 51 tumors, 
‘amplification’ and ‘gain’ of ERBB2 by MLPA were found in 32 tumors (63%) 
and 14 tumors (27%), respectively, and five tumors had peak values of ERBB2 
within the normal range (Table 1). MLPA could detect small ERBB2-amplified 
areas (fraction of approximately 35%), such as in case 47 (Figs. 3A, B and D). 
Cases with smaller fraction of the ERBB2-amplified cells as less than 10% in 
case 13 could be identified as amplification, if samples containing at least 
approximately 30% of ERBB2-amplified cells could be prepared by trimming. 
However, in the five tumors with normal MLPA values, ERBB2-amplified cells 
were confined to minute areas; thus, it was technically difficult to increase the 
fraction of ERBB2-amplified tumor cells.  
In 20 tumors, MLPA samples could be obtained separately from areas with 
positive and negative amplification of ERBB2 (Table 1). The 20 
ERBB2-negative areas of the ERBB2-positive cancers showed neither 
amplification nor gain of ERBB2. The MLPA results of ERBB2 and numbers of 
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tumors with different fractions of the ERBB2-amplified cells were shown 
separately in advanced and early gastric cancers in Figure 2.  
 
Amplification of genes other than ERBB2 
The results of amplification of genes other than ERBB2 were summarized in 
Tables 1 and 2 and representative cases were shown in Figures 3 and 4. 
 
EGFR 
  The two tumors categorized as ‘amplification’ of EGFR by MLPA also 
proved to have the amplification of EGFR by FISH. Among the five tumors 
categorized as ‘gain’, three tumors showed EGFR-amplified cancer cells (Fig. 
3C and E).  By performing FISH after IHC we detected two additional tumors 
with small areas of EGFR amplification. In all seven EGFR-amplified tumors, 
ERBB2- and EGFR-amplified cell populations were found in the vicinity, but 
they were separated and mutually exclusive as shown in Figs. 3A-E. 
 
FGFR2 & MET 
MLPA successfully detected amplifications of FGFR2 in two cases; in 
addition, the ‘gain’ of MET in one of them led to detection of the amplification 
of this gene by FISH. This tumor consisted of ERBB2-positive tubular 
adenocarcinoma and ERBB2-negative poorly differentiated adenocarcinoma, 
and the latter had scattered MET- and FGFR2-amplified cells with mutually 
exclusive distributions, in addition to both negative cells as shown by 
dual-color FISH (Figs. 4A-C).  
 
MYC 
By MLPA analysis, ‘amplification’ and ‘gain’ of MYC were found in four 
and eight tumors, respectively. Gene amplification of MYC was confirmed by 
FISH in all four tumors with ‘amplification’ and in three tumors with ‘gain’. In 
the remaining five tumors with ‘gain’, tumor cells were found to have a few 
additional copy numbers of MYC genes to the number of centromere 8. 
However, their ratios were less than 2.2, and the average copy numbers of 
MYC were less than 7; thus, they were not included in the amplified tumors 
(Suppl Fig. 1).   
Coexistence of amplified MYC and ERBB2 within single nuclei was found in 
four tumors, and MYC/FGFR2, and MYC/EGFR in a case respectively. In a 
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remaining tumor, amplification of ERBB2 and MYC were found in different 
cells. In one of the tumor with co-amplification of MYC and ERBB2 (Case 21), 
and another tumor with co-amplification of MYC and FGFR2 (case 11), the 
co-amplified signals were exclusively overlapped, and appeared as numerous 
scattered signals or tightly clustered signals suggesting that the co-amplified 
genes located on the same amplicons in DM and HSR respectively. (25)  
 
CCND1 
MLPA showed three tumors with amplification of CCND1, and 
amplification was confirmed in the three cases by FISH (Fig. 2F). 
Co-amplification of CCND1 and ERBB2, EGFR, and MYC were found in three 
tumors; however, no discernible correlation between the distributions of 
CCND1 and the co-amplified genes was found in these tumors. 
 
Other genes 
Amplification and gain of TOP2A was found in eight and 15 tumors, 
respectively. Gain of the MDM2 was found in two however they showed no 
amplification by FISH. The other 17 genes detectable by the two MLPA kits 
showed no amplification or gain. 
  
ERBB2–non-amplified tumor 
All the 40 ERBB2-negative control tumors determined by IHC showed normal 
peak values of ERBB2. Thus, the specificity of the MLPA was 100%. Among 
genes with ‘amplification’ or ‘gain’, as shown in Table 2, there were 
amplifications of FGFR2 in three tumors and amplification of MYC, CDK4 
(Suppl Fig. 2) and MDM2 (Suppl Fig. 3) in one tumor each by FISH.  
 
Lymph node status 
Amplified genes in the metastatic cancer cells examined by FISH are shown 





In the present study, the combined analysis of IHC and FISH revealed that 
51 (11%) of 475 of gastric cancers contained ERBB2-amplified cells ranging 
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from less than 10% to almost 100% in each tumor. At the present time there are 
neither definition nor general consensus of intratumoral heterogeneity of 
ERBB2-amplification in gastric cancers. Concerning for breast cancers, the 
College of American Pathologists expert panel has adapted 30% cutoff for the 
homogeneous ERBB2 overexpression, and recommended that cancers 
containing between 5% and 50% of ERBB2-amplified cells, as determined by 
FISH, should be reported as heterogeneous for ERBB2 gene amplification (22). 
In the present study using this cutoff value of 50%, intratumoral 
heterogeneity of ERBB2-amplification was found in 41% (21 of 51)  of 
ERBB2-amplified  tumors, and conversely homogenous ERBB2-amplification 
is 59%. Because molecular target-based therapy with trastuzumab seems to be 
promising for advanced gastric cancers, if we seek cancers with homogeneous 
ERBB2-amplification in advanced gastric cancers, 9.7% (16 of 165 tumors) 
would meet this criterion  
Although the primary aim of the present study was not to evaluate resolving 
power of MLPA, MLPA could successfully identify samples containing as 
small as 30% positive cells as having gene amplification. Thus if MLPA had 
been performed with whole cancer section from the 16 advanced gastric 
cancers with more than 50% amplified cancer cells, the MLPA analyses could 
have identified most of the cases except one as amplification (Fig. 2). A new 
research project may be possible which aims at determining whether MLPA 
can be a really useful clinical test to select trastuzumab-eligible advanced 
gastric cancers.  
Recently, genes encoding RTKs have attracted much attention as targets 
of molecular therapy. An aCGH study reported that ERBB2, FGFR2, EGFR, 
MET and KRAS were fundamentally not co-amplified and estimated that 
approximately 40% of gastric cancer patients may be treatable with 
RTK/RAS-directed therapies (14). Similarly, another FISH study examining 
489 esophagogastric adenocarcinoma described that the amplification of 
ERBB2, MET, and EGFR were, with one exception (MET and EGFR positive), 
mutually exclusive events on a tumor-by-tumor basis, thus about 16% of 
gastric cancer patients are potentially suitable for targeted treatment (26). 
However, co-amplification of RTK genes in single tumors may not be 
infrequent because in present study we limited to the coamplifications of 
ERBB2 and other RTK genes, among 51 ERBB2-amplified tumors 
co-amplification with EGFR occurred in 14% (7/51) of tumors, with FGFR2 in 
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a tumor, and with MET and FGFR2 in a tumor. Theoretically, for the tumors 
having coamplification of ERBB2 and other RTK gene(s) mutually exclusively 
on a cell-by-cell basis, cocktails of trastuzumab and other monoclonal 
antibodies, or trastuzumab and other small molecule inhibitors could be 
candidate treatments. When ERBB2 and EGFR are co-amplified, a dual 
inhibitor of both ERBB2 and EGFR, e.g., lapatinib, may be effective (27).  
The MLPA analysis may provide further useful guide to select 
appropriate molecular targets in gastric cancer. From preliminary analyses 
from a clinical study of breast cancer, the NSABP B-31 trial, it was suggested 
that the tumors with co-amplified HER2 and MYC have a remarkable favorable 
prognosis with adjuvant trastuzumab treatment (28). In an early experimental 
study, small molecule inhibitors of FGFR2 induced apoptosis in SNU 16, 
which has co-amplification of FGFR2 and MYC, but induced only growth 
arrest in KATOIII, which has only FGFR2 amplification (29). Thus, we may 
expect additional effects from co-amplification of MYC in the targeting therapy 
against EGFR2-amplified cancer cells. Furthermore, information of the 
amplification of CCND1 is useful because expression of CCND1 may cause 
resistance to cisplatin, which was co-administered with trastuzumab in the 
ToGA clinical trial. 
Amplification and gain of TOP2A were found in eight ERBB2-amplified 
cancers. TOP2A amplification was exclusively observed with the concomitant 
amplification of ERBB2(9). TOP2A encodes an enzyme required for DNA 
replication, topoisomerase IIα, and clinical studies have confirmed that breast 
cancer patients with TOP2A gene amplification are more sensitive to 
topoisomerase IIα-based therapy (30). As TOP2A resides very close to ERBB2, 
being separated only by approximately 680kb (UCSC Genome Browser on 
Human Feb 2009 Assembly), MLPA may have higher resolving power than 
FISH to determine if the amplicon containing ERBB2 extends to the locus of 
TOP2A. In the present study, two additional candidates for molecular targeting, 
CDK4 and MDM2, were found in ERBB2-non-amplified gastric cancers.  
In conclusion, MLPA is the feasible and easiest tool to collect 
semi-comprehensive information on the ERBB2 and molecular target or 
possible target genes, and useful to plan individualized molecularly targeted 
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Representative cases with different percentages of cells with overexpression 
and amplification of ERBB2. (A, B, C and E, IHC for ERBB2). Arrow pointed 
the small cluster of ERBB2-over expressing cells. (panel B). The region with 
the black rectangle in panel C corresponds to the field in panel D, and panel F 
is a serial section of panel E. FISH demonstrates that the 
ERBB2-overexpressing cells have gene amplification of ERBB2 (D and F: 
orange signals, ERBB2; green signals, centromere 17). (A, case 21; B, case 11; 
C and D, case 18; E and F, case 44) 
 
Figure 2 
Numbers of cases with amplification (black bars), gain (gray bars) and normal 
(white bars) by MLPA in different fractions of FISH-proved ERBB2 amplified 
cells.  
  
Figure 3  
Representative images of co-amplification of ERBB2, EGFR, MYC, CCND1, 
FGFR2. Intramucosal adenocarcinoma with heterogeneous ERBB2 
amplification (A-F, case 47). The circled region with dotted line in panel A 
was used for MLPA analysis. (MLPA peak values: ERBB2, 6.36; EGFR, 1.32, 
MYC, 3.8; CCND1, 3.00) The regions with the black rectangles in panel A 
corresponds to the field in panel B and the field in panel C, respectively. IHC 
shows that approximately 35% of cancer cells in the circled region with dotted 
line in panel A was ERBB2-overexpressing cancer cells (B) and approximately 
6% EGFR-overexpressing cancer cells (C). The regions labeled with d, e, and f 
in panel B and panel C corresponds to the fields in panel D, E, and F 
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respectively. Dual-color FISH shows co-amplifications of ERBB2 and MYC 
(D: orange signals, ERBB2; green signals, MYC), and EGFR and MYC (E: 
orange signals, EGFR; green signals, MYC). Almost all the of cancer cells have 
co-amplification of MYC (orange signals) and CCND1 (green signals) (F) 
Co-amplification of ERBB2 and MYC (G-I) (case 21: MLPA peak values: 
ERBB2, 21.9; MYC, 15.4), and FGFR and MYC (J-L) (case 11:MLPA peak 
values: FGFR2, 62.3; MYC, 15.1) Dual-color FISH showed the signals of 
ERBB2 (orange) and MYC (green) in case 21, and the signals of FGFR2 
(green) and MYC (orange) in case 11 are exclusively overlapped. (G and L, 




Advanced gastric adenocarcinoma with co-amplification of ERBB2, MET, 
and FGFR2 (case 4: MLPA peak values: ERBB2, 3.03; FGFR2, 2.83; MET, 
1.41). Cancer cells in subsets of tubular adenocarcinoma show ERBB2 
amplification (A, dual-color FISH; orange signals, ERBB2; green signals, 
centromere 17) whereas cancer cells of poorly differentiated adenocarcinoma 
show MET amplification or FGFR2 amplification. (dual-color FISH, B and C; 
orange signals, MET; green signals, FGFR2) 
 
Supplemental Figure 1 
 Mean ratio of MYC to CEP8 is 1.9 (case 15). 
 
Supplemental Figure 2 
 Gene amplification of CDK4 in an ERBB2-negative gastric cancer. 
 
Supplemental Figure 3 
Gene amplification of MDM2 in an ERBB2-negative gastric cancer. 
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invasion EGFR FGFR2 MET MYC CCND1 MDM2 TOP2A ERBB2 EGFR FGFR2 MET MYC CCND1 MDM2 TOP2A M Amplified genes
(%) area size (mm)
1 ss 5.24 80 5x3 1.12 1.10 1.08 1.52 0.89 1.14 6.99 0.95 1.51 0.97 1.06 1.06 1.13 1.00 1.09
2 sm 4.65 80 13x3 1.02 1.04 0.96 0.98 1.03 0.83 0.92 1.25 0.84 0.97 0.94 2.12 1.03 0.98 0.84
3 sm 3.39 80 10x3 1.22 0.86 0.84 0.79 0.94 1.33 0.96 0.96 1.07 1.12 1.18 1.05 0.94 1.12 1.03
4 se 3.03 50 6x2 1.00 1.08 1.16 1.02 0.92 1.03 1.20 0.98 0.97 2.83 1.41 1.18 1.13 0.95 1.01 + ERBB2/MET
5 ss 6.08 40 3x1 1.11 1.03 0.87 0.91 1.20 1.00 1.01 1.16 0.97 1.01 1.01 1.17 0.99 0.99 0.96 + ERBB2
6 sm 3.13 30 5x2 1.08 1.06 1.11 1.06 1.00 1.03 1.11 1.05 1.17 1.16 0.92 1.03 1.05 1.00 1.13
7 sm 2.85 30 9x1 0.98 1.02 1.05 1.18 0.88 1.02 1.10 0.93 1.01 1.07 1.01 1.08 0.97 1.03 1.06
8 sm 2.56 30 6x1 0.97 0.96 0.87 1.11 1.04 1.07 1.54 1.07 0.96 1.01 0.91 1.21 1.10 0.89 0.87 + ERBB2
9 m 2.22 20 5x0.5 1.09 1.07 0.97 0.86 0.90 1.08 0.97 0.99 0.80 0.97 0.86 1.25 1.21 1.15 0.92 + Unkown
10 sm 2.21 20 9x0.5 1.02 0.97 0.95 1.02 0.99 0.97 1.98 1.27 1.00 0.97 0.99 0.97 0.99 0.95 1.23
11 sm 1.57 15 5x0.5 1.05 1.19 1.04 1.06 1.00 0.95 1.45 1.09 1.19 62.3 1.08 15.1 1.21 0.90 1.10
12 mp 11.7 <10 8x1 0.87 1.04 1.08 1.06 0.95 1.21 0.90 0.99 1.05 1.08 1.12 1.01 0.89 1.04 0.99
13 ss 7.00 <10 4x3 1.80 0.72 1.58 1.50 0.82 0.94 1.02 0.92 1.60 0.77 1.26 1.44 1.00 0.97 0.95
14 sm 1.60 <10 3x0.5 0.84 1.06 0.77 1.05 1.05 1.19 1.05 0.98 0.96 1.09 1.20 1.19 1.77 0.91 1.03
15 sm 1.60 <10 2x0.5 0.86 1.21 0.83 1.14 0.59 1.35 1.36 0.77 1.08 1.22 1.03 1.63 0.90 0.54 1.36
16 sm 1.38 <10 3x2 16.7 1.22 0.90 1.29 3.47 0.80 1.14 1.11 0.93 1.04 0.94 1.14 0.89 1.07 1.14 + ERBB2
17 mp 1.35 <10 2.0 x1.0 0.89 0.99 1.21 1.04 0.82 1.08 1.58 1.01 1.05 1.03 0.98 1.03 0.98 1.11 1.12 + Unknown
18 m 0.95 <10 0.2 x 0.2 0.94 1.02 0.94 1.00 0.96 1.21 1.21 0.98 1.05 1.06 0.93 1.02 1.01 1.11 1.07
19 ss 0.91 <10 0.5x 0.5 0.91 1.03 1.04 0.98 0.89 1.08 1.09 0.99 0.98 1.04 1.05 0.96 1.02 1.00 1.08
20 sm 0.89 <10 0.5 x 0.5 1.00 1.10 1.27 0.95 0.91 1.10 1.07 1.01 0.77 1.04 0.99 1.03 0.86 1.16 1.01
21 ss 21.9 > 95 10x3 1.22 1.00 0.94 15.4 0.92 0.86 0.87 +  ERBB2
22 ss 12.9 > 95 10x10 1.29 1.09 0.98 1.89 1.29 0.78 2.54
23 ss 9.86 > 95 20x5 0.93 1.02 1.18 1.28 0.90 0.88 1.74 + ERBB2
24 ss 9.20 > 95 25x10 1.00 0.95 1.03 1.11 2.54 1.01 1.15
25 ss 8.18 > 95 15x10 1.21 1.09 1.08 1.00 1.13 0.86 2.52 + ERBB2
26 ss 7.87 > 95 13x10 1.59 1.03 1.09 1.71 0.88 0.79 1.24 + ERBB2
27 ss 5.89 > 95 11x6 1.01 1.05 0.97 1.23 0.83 0.96 2.33
28 sm 5.04 > 95 24x0.5 1.02 0.94 1.07 1.01 0.99 0.90 1.40
29 ss 4.45 > 95 9x5 1.03 0.94 1.03 1.29 0.89 0.76 1.23 + Unkown
30 m 3.99 > 95 10x0.5 1.19 1.03 0.88 0.94 0.85 1.23 1.03
31 m 3.79 > 95 10x1 0.97 1.06 1.08 0.94 0.88 1.11 1.94
32 ss 2.28 > 95 15x15 1.00 0.95 1.09 0.95 0.93 1.07 2.69 + ERBB2
33 m 1.98 > 95 4x1 1.01 0.98 0.98 1.07 1.01 1.01 1.88
34 mp 1.87 > 95 18x2 0.91 1.05 0.94 1.04 1.17 1.20 1.02 + ERBB2
35 m 1.77 > 95 2x0.5 0.97 0.99 0.97 1.07 1.01 0.86 1.29
36 m 1.62 > 95 27x1 1.07 0.97 0.95 1.03 0.94 0.94 1.76
37 ss 2.58 > 95 2x1 0.89 1.01 0.88 1.24 0.98 1.04 1.44 +  ERBB2
38 m 1.41 > 95 4x0.5 0.94 1.07 0.99 1.03 0.94 1.08 1.21
39 m 1.39 > 95 4x0.5 0.99 1.12 1.12 1.07 1.05 1.07 0.98
40 mp 10.7 80 8x6 1.12 0.92 0.97 0.92 1.09 1.26 1.74 + ERBB2
41 m 8.62 80 5x1 1.03 1.03 1.04 0.98 0.97 1.08 1.51
42 m 4.75 80 10x1 0.93 1.17 1.05 0.88 0.85 1.20 1.01
43 si 2.97 80 8x5 1.26 0.90 1.13 1.68 0.97 0.77 3.93 + ERBB2
44 ss 2.55 80 mosaic 1.34 0.77 1.12 1.66 1.02 0.89 2.04
45 m 1.44 80 15x0.5 0.94 1.14 0.93 0.97 0.99 1.04 1.64 +  ERBB2
46 sm 3.78 60 15x1 1.09 1.07 1.08 1.11 1.05 0.95 4.12
47 m 6.36 25 4x1 1.32 1.06 0.91 3.28 3.00 0.93 1.00
48 mp 1.51 20 mosaic 0.95 0.95 0.97 1.39 1.07 1.03 1.03 + Unkown
49 m 1.03 20 0.5x0.5 0.97 1.02 0.98 1.11 1.11 0.91 0.95
50 m 1.07 15 0.2x0.2 0.98 1.04 1.03 0.94 0.95 0.98 1.06
51 ss 1.54 <10 1.0x0.5 10.1 1.14 0.86 1.02 1.22 0.78 1.51
1) Abbreviations: ss, subserosa; sm, submucosa; se, serosa exposed; mp, mucosa propriae; m, mucosa; M, metastasis; +, positive
2) Bold font indicates 'amplification' by MLPA; Italic font indicates 'gain' by MLPA; halftone indicates FISH proved gene amplification
Lymph nodes
                                     Table 1.  Results  of  MLPA analysis of  51 cases with ERBB2  amplification
Case No
ERBB2 -positive area ERBB2 -negative area
ERBB2- positive area
Depth of
invasion MLPA values Fraction (%) area size (mm)
FISH-proved
co-amplified genes MLPA values
FISH-proved
co-amplified genes M Amplified genes
1 ss 5.24 a 80 5x3 0.95 c EGFR
2 sm 4.65 a 80 13x3 1.25
3 sm 3.39 a 80 10x3 0.96 MYC
4 se 3.03 a 50 6x2 0.98 FGFR2, MET + ERBB2/MET
5 ss 6.08 a 40 3x1 EGFR 1.16 + ERBB2
6 sm 3.13 a 30 5x2 1.05
7 sm 2.85 a 30 9x1 0.93
8 sm 2.56 a 30 6x1 1.07 + ERBB2
9 m 2.22 a 20 5x0.5 0.99 + Unkown
10 sm 2.21 a 20 9x0.5 1.27
11 sm 1.57 b 15 5x0.5 1.09 FGFR2, MYC
12 mp 11.7 a <10 8x1 0.99
13 ss 7.00 a <10 4x3 EGFR 0.92
14 sm 1.60 b <10 3x0.5 0.98
15 sm 1.60 b <10 2x0.5 0.77
16 sm 1.38 b <10 3x2 EGFR, CCND1 1.11 + ERBB2
17 mp 1.35 b <10 2.0 x1.0 1.01 + Unknown
18 m 0.95 c <10 0.2 x 0.2 0.98
19 ss 0.91 c <10 0.5x 0.5 0.99
20 sm 0.89 c <10 0.5 x 0.5 1.01
21 ss 21.9 a > 95 10x3 MYC +  ERBB2
22 ss 12.9 a > 95 10x10
23 ss 9.86 a > 95 20x5 + ERBB2
24 ss 9.20 a > 95 25x10 CCND1
25 ss 8.18 a > 95 15x10 + ERBB2
26 ss 7.87 a > 95 13x10 MYC + ERBB2
27 ss 5.89 a > 95 11x6 EGFR
28 sm 5.04 a > 95 24x0.5
29 ss 4.45 a > 95 9x5 + Unkown
30 m 3.99 a > 95 10x0.5
31 m 3.79 a > 95 10x1
32 ss 2.28 a > 95 15x15 + ERBB2
33 m 1.98 b > 95 4x1
34 mp 1.87 b > 95 18x2 + ERBB2
35 m 1.77 b > 95 2x0.5
36 m 1.62 b > 95 27x1
37 ss 2.58 a > 95 2x1 +  ERBB2
38 m 1.41 b > 95 4x0.5
39 m 1.39 b > 95 4x0.5
40 mp 10.7 a 80 8x6 + ERBB2
41 m 8.62 a 80 5x1
42 m 4.75 a 80 10x1
43 si 2.97 a 80 8x5 + ERBB2
44 ss 2.55 a 80 mosaic MYC
45 m 1.44 b 80 15x0.5 +  ERBB2
46 sm 3.78 a 60 15x1
47 m 6.36 a 25 4x1 EGFR, MYC, CCND1
48 mp 1.51 b 20 mosaic MYC + Unkown
49 m 1.03 c 20 0.5x0.5
50 m 1.07 c 15 0.2x0.2
51 ss 1.54 b <10 1.0x0.5 EGFR
 Abbreviations: ss, subserosa; sm, submucosa; se, serosa exposed; mp, mucosa propriae; m, mucosa; si, serosa infiltrating; M, metastasis; +, positive
 MLPA values  >2.0 as amplified a, between 1.3 and 2.0 as gain b ,  and between 0.7 and 1.3 were defined  as normal c.
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Case No
ERBB2 -positive area ERBB2 -negative area Lymph nodes
 Abbreviations: ss, subserosa; sm, submucosa; se, serosa exposed; mp, mucosa propriae; m, mucosa; si, serosa infiltrating; M, metastasis; +, positive
 MLPA values  >2.0 as amplified a, between 1.3 and 2.0 as gain b ,  and between 0.7 and 1.3 were defined  as normal c.
Genes  EGFR  MET  MYC FGFR2 CCND1  CDK4  MDM2  ERBB2 TOP2A
Chromosomal locus 7p11.2 7q31.2 8q24.13 10q26 11q13.3 12q14.1 12q15 17q12 17q21.2
ERBB2  amplification Amplification 2 (2) 0 4 (4) 2 (2) 3 (3) 1 (0) 0 32(32) 8
Positive tumors Gain 5 (3) 2 (1) 8 (3) 0 1 (0) 1 (0) 2 (0) 14 (14) 15
n=51 Normal 44 (2) 49 39 49 47 49 49 5 (5) 28
ERBB2  amplification Amplification 0 0 0 1 (1) 0 0 1 (1) 0 0
Negative tumors Gain 0 1 (0) 2 (1) 2 (2) 0 1 (1) 1 (0 ) 0 0
n=40 Normal 40 39 38 37 40 39 38 40 40
Table 2.Gene amplifications detected by MLPA and FISH
Figures in parentheses are numbers of the tumors whose amplification were proved by FISH.
